Taysha Gene Therapies, Inc. (TSHA) News
Track canonical SquawkNews coverage tagged to TSHA, Taysha Gene Therapies, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ: TSHA ) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per sha
EARNINGS | Aug 11, 2026, 08:00 PM UTC
L
TSHA - Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TSHA - Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 11, 2026, 08:00 PM UTC
L
TSHA - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - Click For
TSHA - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
EARNINGS | Aug 04, 2026, 08:00 PM UTC
M
Taysha Expands Catalent Partnership
Taysha partners with Catalent for manufacturing support
EQUITY | Aug 03, 2026, 12:00 PM UTC
L
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing
() -- Sukumar Nagendran, Director, President and Head of Research and Development, on July 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $1,248,000. Following the Form 4 filing with the SEC, Nagendran
GEOPOLITICS | Jul 13, 2026, 07:58 AM UTC
L
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ: TSHA ) with a Market Outperform and maintains $11 price target.
EQUITY | Jul 02, 2026, 12:56 PM UTC
L
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ: TSHA ) with a Outperform and raises the price target from $12 to $15.
EQUITY | Jun 30, 2026, 11:50 AM UTC
M
TSHA Presents TSHA-102 Data
Taysha Gene Therapies announces multiple presentations highlighting its TSHA-102 clinical program at the 2026 IRSF Rett Syndrome Scientific Meeting
EQUITY | Jun 25, 2026, 08:01 PM UTC
H
SPRY -24% on Update
SPRY falls 24% premarket after providing commercial and financial updates, while other big cap stocks also decline on various news
EQUITY | Jun 25, 2026, 12:17 PM UTC
M
FUL, TCOM, HTZ Drop
H.B. Fuller, Trip.com, and Hertz Global are among the stocks moving lower in Thursday's pre-market session
EQUITY | Jun 25, 2026, 12:08 PM UTC
M
ALOY: Prices $100M Private Placement
ALOY prices private placement of common stock for gross proceeds of approximately $100 million
EQUITY | Jun 25, 2026, 09:49 AM UTC
M
TSHA Prices Public Offering
Taysha Gene Therapies announces pricing of public offering of common stock and pre-funded warrants
EQUITY | Jun 25, 2026, 09:11 AM UTC
M
EXR Prices $550M Notes
EXR prices $550 million of 4.900% senior notes due 2032, while ISPC files Form S-1 and TSHA proposes public offering of common stock and pre-funded warrants
EQUITY | Jun 24, 2026, 09:04 PM UTC
M
TSHA Launches Stock Offering
Taysha Gene Therapies announces proposed public offering of common stock and pre-funded warrants
EQUITY | Jun 24, 2026, 08:01 PM UTC
M
TSHA Completes Dosing
Taysha Gene Therapies completes dosing in REVEAL pivotal trial and reports longer-term clinical data from Part A of REVEAL Phase 1/2 trials for TSHA-102
EQUITY | Jun 22, 2026, 12:02 PM UTC